ReviewCurrent hypertension reports2007
The role of aldosterone in resistant hypertension: implications for pathogenesis and therapy.
Review in Current hypertension reports, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 27 citations in OpenAlex.
- The Mineralocorticoid Receptor in the Vasculature: Friend or Foe?Annual review of physiology · 2024Review
- Molecular Mechanisms of Primary Aldosteronism.Endocrinology and metabolism (Seoul, Korea) · 2019Review
- Baroreflex gain and vasomotor sympathetic modulation in resistant hypertension.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2017Article
- Clinical and pathological analysis of the kidney in patients with hypertensive nephropathy.Experimental and therapeutic medicine · 2013Article
- What can we learn from the American Heart Association and American College of Cardiology expert consensus document on geriatric hypertension?Clinical cardiology · 2012Article
- Resistant hypertension workup and approach to treatment.International journal of hypertension · 2010Article
- Clinical approach in treatment of resistant hypertension.Integrated blood pressure control · 2009Article
- Well tolerated spironolactone-related hyponatremia.Journal of clinical hypertension (Greenwich, Conn.) · 2008Review
- Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome.Journal of the American Society of Hypertension : JASHArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistant hypertension constitutes an increasingly common medical disorder. Although the exact incidence is not precisely known, estimates derived from recent outcome studies emphasize that resistant hypertension is much more common than previously thought. A major advance in our understanding of its pathogenesis and management is the recent recognition of the importance of aldosterone excess or autonomy as an important mechanism for drug resistance in hypertension. Recent studies of the effects of aldosterone on vascular smooth muscle have delineated several extra-renal mechanisms whereby aldosterone produces hypertension primarily by its direct vasoconstrictor effects and by altering vascular compliance. Consequently, aldosterone blockade constitutes an effective intervention for treating resistant hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.